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• In the setting of oligometastatic disease for solid 
malignancies including renal cell carcinoma, melanoma, 
and NSCLC, SABR and PD-1 inhibitor concurrent 
therapy may offer improved outcomes without significant 
additional toxicity. Given the poor outcomes of these 
patients, randomized clinical studies are needed to 
clarify and better define the most appropriate 
combination of RT with check point inhibitors
Metastatic Cancers Treated with Concurrent PD-1 Inhibition
and Stereotactic Ablative Radiotherapy (SABR)
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• We identified 12 patients who have received concurrent 
therapy with SABR and PD-1 inhibitors
• All patients had metastatic disease of various sites and 
refractory to at least a first line chemotherapeutic agent. 
No patients were lost to follow up. Of the 12 patients, 
three (25%) were treated with concurrent therapy twice. 
Of the 15 total PD-1 inhibitor treatments, 10 (67%) were 
with nivolumab while 5 with pembrolizumab (33%)
• Median time from initial cancer diagnosis was 21 
months (range: 11-38 months) with a median follow-up 
of 14 months (range: 6-19 months). The median 
treatment dose and fractions were 40.5 Gy (range 24-54 
Gy) and 5 fr (range 3-9) respectively
• Four lesions (27%) were noted to undergo local 
progression at time of analysis. In these patients, local 
progression was noted a median of 3.5 months 
following radiation (range 1-8 months)
• A total of five patients had died at the time of study 
analysis (42%). Median OS for all patients from the date 
of primary cancer diagnosis was 72 months
• In this novel analysis of solid tumor oligometastases treated 
with SABR concurrently with anti-PD-1 therapy, we found 
no increased toxicity with combination therapy
• Studies using mouse models in the preclinical setting have 
provided strong evidence to support combination 
treatments in patients with multiple solid tumors
• This potential immunogenic effect of ablative radiation 
doses may potentially a path to improve overall survival and 
progression free survival in future cancer therapies. Given 
our remarkable OS with such dismal malignancies, we find 
that treatment in the concurrent setting has the potential to 
upregulate the tumor specific antigenic exposure and 
improve both local control and potentially distal control
• Multiple other recent clinical studies have confirmed 
improved OS with the use of PD-1 therapy and radiation. 
Nevertheless, the optimal sequence and dosage of both 
SABR as well as PD-1 inhibitors has yet to be established. 
Given our findings as well as the promising data of other 
cohorts, further prospective analyses should be pursued
• This was an IRB approved retrospective cohort study of 
patients with solid tumor metastases
• We gathered tumor registry data of patients who 
received concurrent SABR and anti-PD-1 between 
January 1 2015 and December 31 2016
• Local progression was assessed using response 
evaluation criteria in solid tumors (RECIST) and 
categorized as partial, stable, or progressive
• Overall survival was also calculated using the Kaplan–
Meier method, with the log-rank test, Tarone-Ware, and 
Breslow used to test differences between groups. Cox 
proportional hazard model analyses were also carried 
out







• Metastatic solid tumor disease portends poor 
outcomes and is often refractory to first line therapy. 
Immune therapy has become a viable alternative
• In recent years, check point inhibitors have become a 
paradigm shifting modality of treatment in malignancy 
trailblazing a new class of cancer treatment. Ablative 
radiotherapy has been shown to increase response 
rates by virtue of creating a more penetrative tumor 
microenvironment thus exposing certain malignant-
specific antigens and further recruitment of immune 
responsive cells
• Novel evidence has shown the synergistic effect of 
checkpoint inhibitors and ablative radiotherapy. Our 
institution has been treating patients with concurrent 
SABR and PD-1 therapy for multiple solid tumor 
malignancies including renal, melanomatous, and 
lung cancers
Variable n %
No. of Patients 12  
No. of PD-1 Treatments 15  
Type of PD-1 Inhibitor    
Pembrolizumab       5  33%













Enrolled on clinical trial  
Y 5 42%
N 7 58%










Median (months) 14  
Range (months) 6-19  
Time from Primary Diagnosis to Radioembolization
Median (months) 21  










• The purpose of this study is to assess the toxicities and 
health outcomes in all patients concurrently treated with 
SABR and anti-PD-1 therapy for solid tumors
Problem Statement
Table 1 Patient Characteristics
Figure 1 Immunogenic Cell Death 
Stress Induced by Radiation Leads to Antigen Exposure to the Adaptive 
Immune System
Table 2 Lesion Characteristics
